Biogen Can't Demand Royalties After Patent Expired, Suit Says
A New Jersey-based Biogen licensee slapped the drugmaker with a lawsuit Wednesday for allegedly trying to collect royalties for sales of Biogen's anticoagulant drug after its patent expired, in breach of...To view the full article, register now.
Already a subscriber? Click here to view full article